The PROSPERITIT study has its first patient

Masaryk University in cooperation with the Department of Pediatric Oncology of the University Hospital Brno and the Department of Pediatric Hematology and Oncology of the University Hospital Motol is conducting a research study entitled “Pediatric prospective personalized study identifying immune and molecular therapeutic targets (PROSPERITIT)”. The primary goal of the project is to evaluate the feasibility of genetic testing to determine the best treatments for high-risk pediatric patients with brain and spinal cord tumors. These assays will be performed using a panel of selected genes (F1 Heme from Foundation Medicine). The expected number of patients enrolled in the study in the Czech Republic is 40, and on February 4, the first patient was enrolled.